Post Partum Depression (Maternal Depression / Postnatal Depression) is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Post Partum Depression (Maternal Depression / Postnatal Depression) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Post Partum Depression (Maternal Depression / Postnatal Depression) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Post Partum Depression (Maternal Depression / Postnatal Depression) overview
Post Partum Depression also known as maternal depression and postnatal depression is a medical condition occurs during the pregnancy or after giving the birth (post-partum). Most common condition is prevalent in 1 in 7 women. Many factors like anxiety during the trimester, psychological factors, social support, lifestyle changes, and hormonal changes can cause this condition. Most of the cases are left untreated because of the stigmas attached to it. Persistent feelings of sadness, fatigue, lack of contact with people, loss of appetite, sleep disturbances, and frightening thoughts are some common symptoms. Cognitive behavioral therapy and anti-depressants are treatment strategies. Selective Serotonin reuptake inhibitors (SSRIs) are the first-choice antidepressants.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Post Partum Depression (Maternal Depression / Postnatal Depression), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
